MA23744A1 - Procede pour la preparation de sulfonamides, compositions pharmaceutiques les contenant et leur utilisation - Google Patents
Procede pour la preparation de sulfonamides, compositions pharmaceutiques les contenant et leur utilisationInfo
- Publication number
- MA23744A1 MA23744A1 MA24095A MA24095A MA23744A1 MA 23744 A1 MA23744 A1 MA 23744A1 MA 24095 A MA24095 A MA 24095A MA 24095 A MA24095 A MA 24095A MA 23744 A1 MA23744 A1 MA 23744A1
- Authority
- MA
- Morocco
- Prior art keywords
- pct
- pharmaceutical compositions
- compositions containing
- sulfonamides
- preparation
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
- 102000002045 Endothelin Human genes 0.000 abstract 2
- 108050009340 Endothelin Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Bipolar Transistors (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Surgical Instruments (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Steroid Compounds (AREA)
- Lubricants (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH383794 | 1994-12-20 | ||
| CH241995 | 1995-08-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA23744A1 true MA23744A1 (fr) | 1996-07-01 |
Family
ID=25690401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA24095A MA23744A1 (fr) | 1994-12-20 | 1995-12-15 | Procede pour la preparation de sulfonamides, compositions pharmaceutiques les contenant et leur utilisation |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6004965A (enExample) |
| EP (1) | EP0799209B1 (enExample) |
| JP (1) | JP2989014B2 (enExample) |
| KR (1) | KR100445085B1 (enExample) |
| CN (1) | CN1098254C (enExample) |
| AT (1) | ATE246681T1 (enExample) |
| AU (1) | AU701767B2 (enExample) |
| BR (1) | BR9510104A (enExample) |
| CA (1) | CA2208018C (enExample) |
| CY (1) | CY2495B1 (enExample) |
| CZ (1) | CZ287916B6 (enExample) |
| DE (1) | DE69531457T2 (enExample) |
| DK (1) | DK0799209T3 (enExample) |
| ES (1) | ES2203649T3 (enExample) |
| FI (1) | FI120397B (enExample) |
| HU (1) | HU228619B1 (enExample) |
| IL (1) | IL116385A (enExample) |
| MA (1) | MA23744A1 (enExample) |
| MY (1) | MY131126A (enExample) |
| NO (1) | NO316645B1 (enExample) |
| NZ (1) | NZ297797A (enExample) |
| PT (1) | PT799209E (enExample) |
| SA (1) | SA95160421B1 (enExample) |
| TW (1) | TW313568B (enExample) |
| WO (1) | WO1996019459A1 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6063911A (en) * | 1993-12-01 | 2000-05-16 | Marine Polymer Technologies, Inc. | Methods and compositions for treatment of cell proliferative disorders |
| TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
| ATE406176T1 (de) | 1996-12-06 | 2008-09-15 | Amgen Inc | Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten |
| EP0897914B1 (en) | 1997-08-19 | 2004-05-26 | F. Hoffmann-La Roche Ag | Process for the preparation of 2,5-disubstitued pyridines |
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
| EP0979822B1 (en) * | 1998-08-10 | 2005-11-30 | F. Hoffmann-La Roche Ag | Process for the preparation of 2-carbamoyl-pyridines |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
| RU2319693C9 (ru) | 1999-01-13 | 2008-08-20 | Байер Копэрейшн | Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты) |
| ES2377847T3 (es) | 1999-01-13 | 2012-04-02 | Bayer Healthcare Llc | Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38 |
| US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| TWI284642B (en) | 1999-01-18 | 2007-08-01 | Hoffmann La Roche | Novel heterocyclic sulfonamides |
| US6417360B1 (en) * | 1999-03-03 | 2002-07-09 | Hoffmann-La Roche Inc. | Heterocyclic sulfonamides |
| AU747596B2 (en) * | 1999-05-22 | 2002-05-16 | Actelion Pharmaceuticals Ltd | Aqueous pharmaceutical composition |
| ZA200002318B (en) * | 1999-05-22 | 2000-11-16 | Actelion Pharmaceuticals Ltd | Aqueous pharmaceutical composition. |
| CA2315614C (en) | 1999-07-29 | 2004-11-02 | Pfizer Inc. | Pyrazoles |
| NZ512526A (en) * | 1999-09-03 | 2004-01-30 | Actelion Pharmaceuticals Ltd | 4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin. |
| MXPA02006250A (es) * | 1999-12-22 | 2004-09-06 | Actelion Pharmaceuticals Ltd | Derivados de butino diol. |
| AU2001265871A1 (en) * | 2000-04-25 | 2001-11-07 | Actelion Pharmaceuticals Ltd | Substituted sulfonylaminopyrimidines |
| US6387915B2 (en) | 2000-05-31 | 2002-05-14 | Pfizer Inc. | Isoxazole-sulfonamide endothelin antagonists |
| US6670362B2 (en) | 2000-09-20 | 2003-12-30 | Pfizer Inc. | Pyridazine endothelin antagonists |
| US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| PT1345920E (pt) | 2000-12-18 | 2006-08-31 | Actelion Pharmaceuticals Ltd | Novas sulfonamidas e sua utilizacao como antagonistas dos receptores de endotelina |
| US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| WO2002083650A1 (en) * | 2001-04-11 | 2002-10-24 | Actelion Pharmaceuticals Ltd | Novel sulfonylamino-pyrimidines |
| US7371763B2 (en) | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| ES2378670T3 (es) | 2002-02-11 | 2012-04-16 | Bayer Healthcare, Llc | Aril ureas como inhibidores de cinasas |
| DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
| AU2003209119A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| US20040002451A1 (en) | 2002-06-20 | 2004-01-01 | Bruce Kerwin | Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing |
| BR0316724A (pt) * | 2002-12-02 | 2005-10-18 | Actelion Pharmaceuticals Ltd | Compostos, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| PL1626714T3 (pl) | 2003-05-20 | 2007-12-31 | Bayer Healthcare Llc | Diarylowe pochodne mocznika do schorzeń, w których pośredniczy PDGFR |
| CA2532865C (en) | 2003-07-23 | 2013-08-06 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the inhibition of kinase signaling |
| GB0327839D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
| TW200605867A (en) | 2004-03-17 | 2006-02-16 | Novartis Ag | Use of organic compounds |
| TW200628467A (en) | 2004-11-11 | 2006-08-16 | Actelion Pharmaceuticals Ltd | Novel sulfamides |
| US7402730B1 (en) | 2005-02-03 | 2008-07-22 | Lexicon Pharmaceuticals, Inc. | Knockout animals manifesting hyperlipidemia |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| PL2049517T3 (pl) | 2006-07-20 | 2014-06-30 | Novartis Ag | Pochodne amino-piperydyny jako inhibitory CETP |
| AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
| EA019661B1 (ru) | 2006-12-08 | 2014-05-30 | Лексикон Фармасьютикалз, Инк. | Моноклональные антитела против angptl3 |
| AU2008219065B2 (en) | 2007-02-19 | 2014-01-30 | Marine Polymer Technologies, Inc. | Hemostatic compositions and therapeutic regimens |
| MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| FR2921062A1 (fr) * | 2007-09-17 | 2009-03-20 | Commissariat Energie Atomique | Composes utiles comme ligands et notamment comme chromophores organiques de complexation des lanthanides et leurs applications |
| EP2463282B1 (en) | 2007-11-05 | 2013-08-07 | Novartis AG | 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis |
| PT2229356E (pt) | 2007-12-03 | 2012-01-20 | Novartis Ag | Derivados de 4-benzilamino-pirrolidina 1,2-dissubstituídos como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose |
| CN102803217B (zh) | 2009-05-15 | 2015-06-17 | 诺华股份有限公司 | 作为醛固酮合酶抑制剂的芳基吡啶 |
| CA2761853A1 (en) | 2009-05-15 | 2010-11-18 | Novartis Ag | Benzoxazolone derivatives as aldosterone synthase inhibitors |
| AR076707A1 (es) | 2009-05-28 | 2011-06-29 | Novartis Ag | Derivados amino-propionicos sustituidos como inhibidores de neprilisina |
| ES2582395T3 (es) | 2009-05-28 | 2016-09-12 | Novartis Ag | Derivados aminobutíricos sustituidos como inhibidores de neprilisina |
| ES2551002T3 (es) | 2009-11-17 | 2015-11-13 | Novartis Ag | Derivados de aril-piridina como inhibidores de la aldosterona sintasa |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| ES2472446T3 (es) | 2009-11-30 | 2014-07-01 | Novartis Ag | Derivados de imidazol como inhibidores de aldosterona sintasa |
| US8858964B2 (en) | 2010-04-15 | 2014-10-14 | Marine Polymer Technologies, Inc. | Anti-bacterial applications of poly-N-acetylglucosamine nanofibers |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| PT2643019T (pt) | 2010-11-24 | 2019-04-23 | Lexicon Pharmaceuticals Inc | Anticorpos para notum pectinacetilesterase |
| WO2012142581A1 (en) | 2011-04-15 | 2012-10-18 | Marine Polymer Technologies, Inc. | Treatment of disease with poly-n-acety glucosamine nanofibers |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| US9383357B2 (en) | 2012-12-07 | 2016-07-05 | Northwestern University | Biomarker for replicative senescence |
| KR20150119109A (ko) | 2013-02-14 | 2015-10-23 | 노파르티스 아게 | Nep (중성 엔도펩티다제) 억제제로서의 치환된 비스페닐 부타노익 포스폰산 유도체 |
| EA201690282A1 (ru) | 2013-07-25 | 2016-09-30 | Новартис Аг | Биоконъюгаты синтетических апелиновых полипептидов |
| EA201690278A1 (ru) | 2013-07-25 | 2016-06-30 | Новартис Аг | Циклические полипептиды для лечения сердечной недостаточности |
| PE20171328A1 (es) | 2015-01-23 | 2017-09-12 | Novartis Ag | Conjugados de acidos grasos y apelina sintetica con mayor vida media |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| TWI835843B (zh) | 2018-10-03 | 2024-03-21 | 瑞士商亨斯邁紡織染化（瑞士）有限公司 | 新的經吡啶及經嘧啶取代之三ｕｖ吸收劑 |
| JP2023548185A (ja) * | 2020-11-05 | 2023-11-15 | イドーシア ファーマシューティカルズ リミテッド | クラゾセンタン二ナトリウム塩の安定な結晶性水和物 |
| EP4582086A3 (en) | 2021-12-17 | 2025-07-23 | Idorsia Pharmaceuticals Ltd | Clazosentan disodium salt, its preparation and pharmaceutical compositions comprising the same |
| US20250228835A1 (en) * | 2024-01-12 | 2025-07-17 | Rectify Pharmaceuticals, Inc. | Pyridinyloxypyridines and related compounds and their use in treating medical conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW270116B (enExample) * | 1991-04-25 | 1996-02-11 | Hoffmann La Roche | |
| RU2086544C1 (ru) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| TW287160B (enExample) * | 1992-12-10 | 1996-10-01 | Hoffmann La Roche | |
| TW394761B (en) * | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
| IL111959A (en) * | 1993-12-17 | 2000-07-16 | Tanabe Seiyaku Co | N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them |
-
1995
- 1995-11-11 TW TW084111957A patent/TW313568B/zh not_active IP Right Cessation
- 1995-11-29 SA SA95160421A patent/SA95160421B1/ar unknown
- 1995-12-08 AU AU43041/96A patent/AU701767B2/en not_active Expired
- 1995-12-08 JP JP8519469A patent/JP2989014B2/ja not_active Expired - Lifetime
- 1995-12-08 KR KR1019970704135A patent/KR100445085B1/ko not_active Expired - Lifetime
- 1995-12-08 NZ NZ297797A patent/NZ297797A/en not_active IP Right Cessation
- 1995-12-08 AT AT95941706T patent/ATE246681T1/de active
- 1995-12-08 ES ES95941706T patent/ES2203649T3/es not_active Expired - Lifetime
- 1995-12-08 HU HU9702407A patent/HU228619B1/hu unknown
- 1995-12-08 CA CA002208018A patent/CA2208018C/en not_active Expired - Lifetime
- 1995-12-08 DK DK95941706T patent/DK0799209T3/da active
- 1995-12-08 US US08/860,107 patent/US6004965A/en not_active Expired - Lifetime
- 1995-12-08 EP EP95941706A patent/EP0799209B1/en not_active Expired - Lifetime
- 1995-12-08 BR BR9510104A patent/BR9510104A/pt not_active IP Right Cessation
- 1995-12-08 WO PCT/EP1995/004843 patent/WO1996019459A1/en not_active Ceased
- 1995-12-08 CN CN95196948A patent/CN1098254C/zh not_active Expired - Lifetime
- 1995-12-08 DE DE69531457T patent/DE69531457T2/de not_active Expired - Lifetime
- 1995-12-08 PT PT95941706T patent/PT799209E/pt unknown
- 1995-12-08 CZ CZ19971874A patent/CZ287916B6/cs not_active IP Right Cessation
- 1995-12-14 IL IL11638595A patent/IL116385A/xx not_active IP Right Cessation
- 1995-12-15 MA MA24095A patent/MA23744A1/fr unknown
- 1995-12-18 MY MYPI95003923A patent/MY131126A/en unknown
-
1997
- 1997-06-04 NO NO19972538A patent/NO316645B1/no not_active IP Right Cessation
- 1997-06-18 FI FI972628A patent/FI120397B/fi not_active IP Right Cessation
-
2004
- 2004-12-14 CY CY0400089A patent/CY2495B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA23744A1 (fr) | Procede pour la preparation de sulfonamides, compositions pharmaceutiques les contenant et leur utilisation | |
| DZ1794A1 (fr) | Nouvelle formule pharmaceutique. | |
| ATE177421T1 (de) | Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen | |
| HUT77627A (hu) | 2,2-Diklór-alkánkarbonsavak, eljárás előállításukra és ezeket tartalmazó, inzulinrezisztencia kezelésére alkalmazható gyógyszerkészítmények | |
| RU94031102A (ru) | Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний | |
| DE59511017D1 (de) | [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE | |
| BR9713921A (pt) | Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa | |
| TR199701121T1 (xx) | Benazepril veya benazeprilat ve valsartan i�eren kombinasyon bile�imleri. | |
| ATE179164T1 (de) | Hiv-proteaseinhibitoren | |
| DE69329687D1 (de) | Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus | |
| YU17999A (sh) | Novi derivati pentaeritrita, njihova izrada i primena kao i međuproizvodi za njihovu sintezu | |
| ATE205473T1 (de) | Neue borneolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung | |
| DE59504643D1 (de) | Neue phosphanoxide, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel | |
| FR2427822A1 (fr) | Medicament pour le traitement des maladies circulatoires, a base de 5-methyl-7-dimethylamino-s-triazolo (1,5-a) pyrimidine | |
| NO974687D0 (no) | Kondenserte <beta>-carboliner | |
| ATE312611T1 (de) | Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen |